Report Library
All Reports
2014 BioMedTracker Post-ESMO Report
October 13, 2014
The European Society for Medical Oncology 2014 Annual Meeting (ASCO) was held in Madrid, Spain from September 26-30 and is the
premier scientific meeting in oncology in Europe. While the meeting often suffers from its proximity to ASCO, this year’s meeting included a
number of important data releases, especially for lung cancers.
This post-report highlights major ESMO presentations and analyses that were added to BioMedTracker as well as a list of all events added
to BioMedTracker in conjunction with the meeting. Highlights included:
- Anamorelin for Cachexia/Weight Loss (Helsinn). Mixed data were presented from the two Phase III – ROMANA studies which met only one of two co-primary endpoints. The drug now faces an uphill battle to gain approval.
- Vintafolide for NSCLC (ECYT). Updated data were presented from the Phase IIb – TARGET study that suggested a promising subgroup for a pivotal Phase III study which may be conducted even without a partner.
- Neratinib for NSCLC (PBYI). Although most advanced in its development for breast cancer, an update from a small NSCLC study suggested that the diarrhea AE that has plagued development can be controlled using prophylactic treatment.
- Cobimetinib for Melanoma (Roche). The first quantitative data were released from the pivotal Phase III study and should set the stage for regulatory filings, including a European MAA that was disclosed with the data release.
- Gilotrif for Head & Neck Cancer (Boehringer). Top-line results from the pivotal LUX-Head & Neck 1 study were somewhat mixed with a minimal OS benefit, but several other large studies have yet to read out.
| Disease Group Covered: |
Endocrine
Metabolic Oncology |
| Indications Covered: |
Castleman's Disease
Dysmenorrhea |
Additional Resources: